Skip to main content

Table 2 Baseline comparison between treatment and placebo groups

From: House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care [ISRCTN63308372]

Variable HDM impermeable bedding, n = 26 Placebo bedding, n = 21
Age, mean (sd) 10.58 (2.34) 11.57 (2.08)
Males (%) 16 (62) 13 (62)
Peak expiratory flow in litres/min, mean (sd) 288.80 (100.80) 328.57 (73.02)
Number on inhaled steroids (%) 5 (19.2) 5 (23.8)
28-day asthma symptom score (0–336), median (inter-qaurtile range) 12.0 (6.5 to 52.5) 37.0 (9.0 to 69.0)
28-day rhinitis symptom score (0–252), median (inter-quartile range) 50.5 (19.8 to 82.5) 51.0 (23.5 to 84.5)
Episodes of night-time waking over 28 days, median (inter-quartile range) 0 (0 to 0.75) 0 (0 to 3.0)
28-day dose inhaled steroid mcg/month, median (inter-quartile range) 5600 (1450 to 11,100) 5400 (58 to 11,200)
28-day dose bronchodilator mcg/month, median (inter-quartile range) 800 (125 to 1700) 400 (100 to 42)